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Abstract – Docosahexaenoic acid (DHA) has been postulated to extend the period of gestation, increase birth weight,
enhance neurodevelopment and reduce the risk of allergic disease. Because of its large sample size and relatively broad
inclusion criteria, the DOMInO (DHA to Optimise Mother Infant Outcome) trial oﬀers the opportunity to explore the
eﬀect of prenatal DHA supplementation of multiple outcomes. Overall, the DOMInO trial showed that prenatal DHA
supplementation increases the length of gestation, reduces the risk of early preterm and low birth weight, has little or no
eﬀect on maternal postpartum depression and early childhood neurodevelopment but reduces the risk of atopic eczema
and sensitisation in the first year of life. The clinical utility of prenatal DHA supplementation of reducing early birth is
important and requires further investigation.
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Résumé – Comprendre les eﬀets de la supplémentation en acide docosahexaénoïque (DHA) pendant la grossesse
sur de multiples paramètres à partir de l’étude DOMIn0. Il a été envisagé que l’acide docosahexaénoïque (DHA)
puisse prolonger la période de gestation, augmenter le poids de naissance, renforcer le développement neurologique
et réduire le risque de maladie allergique. En raison de la grande taille de son échantillon et de critères d’inclusion
relativement larges, l’étude DOMInO (DHA to Optimise Mother Infant Outcome) oﬀre l’occasion d’explorer l’eﬀet
d’une supplémentation prénatale en DHA sur de multiples paramètres. Dans l’ensemble, l’étude DOMInO a montré
que la supplémentation prénatale en DHA augmente la durée de la gestation, réduit le risque de prématurité précoce
et de faible poids de naissance, a peu ou pas d’eﬀet sur la dépression maternelle post-partum et sur le développement
neurologique durant la petite enfance, mais réduit le risque d’eczéma atopique et de sensibilisation dans la première
année de la vie. L’utilité clinique d’une supplémentation prénatale en DHA afin de réduire les naissances avant terme
est importante et nécessite une enquête plus approfondie.
Mots clés : DHA / grossesse / développement de l’enfant / allergies de l’enfant
1 Introduction
The n-3 long chain polyunsaturated fatty acid (LCPUFA),
docosahexaenoic acid (DHA), has multiple biochemical and
physiological roles in many organ systems. This is perhaps not
surprising as DHA is an integral part of all cell membranes.
It also naturally follows that DHA has a number of postulated
clinical eﬀects, especially in the perinatal period which is a pe-
riod characterized by anabolic change and organ growth. Some
of the postulated eﬀects of DHA in the perinatal period are
to extend gestational length, enhance early childhood neuro-
 Correspondence: maria.makrides@sa.gov.au
development and to ameliorate or prevent the development of
allergic disease. While various clinical studies have evaluated
the eﬀect of DHA supplementation during pregnancy, it has
been diﬃcult to elucidate the extent of benefit for general pop-
ulations as diﬀerent studies have been specifically designed
to assess particular outcomes. For example, many studies de-
signed to assess the eﬀect of DHA supplementation during
pregnancy on childhood neurodevelopmental outcomes have
excluded children born prematurely and do not contain data
relating to the duration of pregnancy. Because of its large sam-
ple size and relatively broad inclusion criteria, the DOMInO
(DHA to Optimise Mother Infant Outcome) trial oﬀers the
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opportunity to explore the eﬀect of prenatal DHA supplemen-
tation of multiple outcomes. The purpose of this paper is to
bring together the core outcomes of the DOMInO trial reported
to date and consider the current evidence as well as the re-
search gaps for further investigation.
2 The DOMInO trial
The DOMInO trial is a multi-center, double-blind random-
ized controlled trial that was originally designed to test the
eﬀect of DHA supplementation during the last half of preg-
nancy on reducing the symptoms of post-partum depression
and enhancing early childhood development (DOMInO Trial:
ACTRN12605000569606). The DOMInO trial is the largest
DHA supplementation study in pregnancy reported to date,
and the methods have been previously published (Makrides
et al., 2010). To summarize, women at 5 study sites around
Australia, with singleton pregnancies less than 21 weeks ges-
tation were invited to participate (between October 2005–
January 2008). Women were excluded if they were already
taking a supplement containing DHA, their fetus had a known
major abnormality, they had a bleeding disorder in which fish
oil was contraindicated, were taking anticoagulant therapy, had
a documented history of drug or alcohol abuse, were participat-
ing in another fatty acid trial, were unable to give written or in-
formed consent or if English was not the main language spoken
at home. Enrolled women were assigned a unique study num-
ber corresponding to allocation of a treatment pack through
a computer driven telephone randomization service according
to an independently generated randomization schedule, strati-
fied by center and parity. Women allocated to the DHA group
were asked to consume three 500 mg capsules per day of
DHA-rich fish oil providing ∼800 mg/d DHA and 100 mg/d
of eicosapentaenoic acid (EPA) (Incromega 500 TG, Croda
Chemicals, East Yorkshire, England) and women in the control
group were asked to consume three 500 mg vegetable oil (rape-
seed, sunflower and palm oil) capsules (without DHA) per day,
from study entry until birth. All capsules were identical in
size, shape and color and donated by Efamol, Surrey, England.
A total of 2399 women were randomized into the DOMInO
trial. Of these, 1197 were randomly assigned to treatment with
DHA and 1202 to control treatment. Outcome measures for the
DOMInO trial included major pregnancy and birth outcomes,
maternal symptoms of post-partum depression, as well as neu-
rodevelopment and allergic disease in early childhood for spe-
cific subgroups of children.
3 Outcome assessments
Pregnancy outcome data were collected via a blinded re-
view of women’s and infant’s medical records including dura-
tion of gestation, the frequency of preterm birth < 37 weeks’
gestation and early preterm birth < 34 weeks gestation, gesta-
tional diabetes mellitus (GDM), preeclampsia and pregnancy
induced hypertension (Makrides et al., 2010; Zhou et al.,
2012). Other outcomes included small for gestational age for
weight, length, and head circumference was defined as below
the 10th percentile for birth weight, length, and head circum-
ference, and large for gestational age for weight, length, and
head circumference was defined as below the 90th percentile
for birth weight, length, and head circumference for the corre-
sponding gestational age and sex. Perinatal death was defined
as stillbirth or death within the first 28 days of life.
Postpartum Depression was assessed using the self-
reported Edinburgh Postnatal Depression Scale (EPDS) ques-
tionnaire in English at six weeks and six months Postpartum
(Cox et al., 1987). Validation studies indicate high sensitivity
(68–95%) and high specificity (78–96%) of the EPDS against a
clinical psychiatric diagnosis of PPD (Cox et al., 1987; Boyce
et al., 1993; Murray and Carothers, 1990). A score of more
than 12 on the EPDS is widely used to indicate a probable de-
pressive disorder (Hiscock and Wake, 2001; Murray, 1992).
Neurodevelopment at 18 months and 4 years: a subset
of infants, consisting of 630 randomly selected term infants
and 96 preterm infants, from two centres in Adelaide were
selected for neurodevelopmental assessments at 18 months
and 4 years of age. Assessments were performed by study psy-
chologists who were blinded to treatment group allocation and
previous results. Infants were assessed with the Bayley Scales
of Infant and Toddler Development, Third Edition (Bayley-
III) at 18 months (Bayley, 2006). Child neurodevelopment
at 4 years was assessed using the General Conceptual Abil-
ity (GCA) score of the Diﬀerential Ability Scales Second
Edition (DAS II) (Elliot, 2007). The Bayley-III and DAS II
have age-standardized scores with a mean of 100 and SD of
15 (range 50–150). Standardized scores more than one SD be-
low the mean (< 85) were considered delayed. For children
born preterm, their corrected age was used to standardize test
scores.
Allergy assessments at 1 and 3 years of age: infants whose
mothers were enrolled at either of two centres in Adelaide and
who had a first-degree relative with medically diagnosed al-
lergic disease (asthma, allergic rhinitis, eczema) were eligi-
ble for the allergy follow-up. Medically diagnosed atopic (or
IgE associated) disease at 1 and 3 years, defined as a posi-
tive skin prick test together with clinical symptoms of allergy
(eczema, asthma, allergic rhinitis or food allergy) was assessed
by blinded study doctors (Palmer et al., 2013). A total of
n = 706 women enrolled, with n = 368 women in the interven-
tion group and n = 338 women in the control group. At 1 year
of age, the food allergens tested were whole hens’ egg, cows’
milk, wheat, tuna and peanut, and the aeroallergens tested
were ryegrass pollen, olive tree pollen, Alternaria tenuis, cat
hair and house dust mite (Dermatophagoides pteronyssinus).
At 3 years of age, the same allergens were tested with the
addition of two foods (cashew nut and sesame seed) and one
aeroallergen (house dust mite, Dermatophagoides farinae).
4 Outcome data from the DOMInO trial
Pregnancy outcomes: there were fewer very preterm births
(< 34 weeks’ gestation) in the DHA group compared with
the control group (1.09% vs. 2.25%; adjusted RR, 0.49; 95%
CI, 0.25–0.94; P = 0.03) and this was associated with fewer
infants requiring admission to neonatal intensive care in the
DHA group (1.75% vs. 3.08%, RR 0.57; 95% CI 0.34–0.97;
P = 0.04) (Makrides et al., 2010). However, DHA supple-
mentation resulted in more postterm births requiring obstet-
ric intervention (inductions or cesarean deliveries) compared
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with the control group (17.59% vs. 13.72%; adjusted RR, 1.28;
95% CI, 1.06–1.54; P = 0.01) (Makrides et al., 2010). This
overall shift in the length of gestation resulted in a higher
mean birth weight (68 g, 95% CI, 23–114 g; P = 0.003) and
fewer infants of low birth weight (3.41% vs. 5.27%; adjusted
RR, 0.65; 95% CI, 0.44–0.96; P = 0.03) in the DHA group
compared with the control group. Mean birth weight z scores
(corrected for gestational age and sex) did not diﬀer between
groups, strongly indicating that group diﬀerences in birth size
were largely a function of gestational age at birth (Makrides
et al., 2010). No statistically significant diﬀerences in the RR
of small for gestational age or large for gestational age for
weight, length, or head circumference were found between the
groups. Five infants had brain injury at birth and 5 had neona-
tal convulsion in the control group compared with none in the
DHA rich fish-oil group (P = 0.03). There were 12 perina-
tal deaths among infants of control mothers and 3 among in-
fants of the fish-oil – supplemented mothers (P = 0.03). No
diﬀerences were observed between the groups in other preg-
nancy or perinatal complications, including the incidence of
GDM, PE, pregnancy induced hypertension, and neonatal hy-
poglycaemia, resuscitation at birth or other neonatal complica-
tions (Zhou et al., 2012). The tantalising data suggesting that
supplementation with 800 mg of DHA per day can reduce the
risk of early preterm birth by about 50% is consistent with the
Cochrane systematic review that was completed before the in-
clusion of the DOMInO trial and included trials that largely
supplemented pregnant women with marine oil dominant in
EPA rather than DHA. While n-3 LCPUFA supplementation
during pregnancy appears to increase the length of gestation,
the clinical utility of our findings and their incorporation into
clinical practice guidelines requires further work.
Postpartum Depression: the percentage of women with
depressive symptoms (EPDS score > 12) during the first
6 months postpartum did not diﬀer between the DHA and
control groups (9.67% vs. 11.19%; adjusted RR, 0.85; 95%
CI, 0.70–1.02; P = 0.09) (Makrides et al., 2010). Depressive
symptoms were more common among women with a previ-
ous or current diagnosis of depression at trial entry, but did
not diﬀer between groups. The percentage of women with a
new medical diagnosis for depression during the trial or a di-
agnosis requiring treatment also did not diﬀer between groups
(Makrides et al., 2010). Overall, our data do not support DHA
supplementation during pregnancy as a strategy to prevent
post-partum depression.
Neurodevelopment of children at 18 months and 4 years:
at 18 months of age, mean cognitive composite scores (ad-
justed mean diﬀerence, 0.01; 95% CI, −1.36 to 1.37; P = 0.99)
and mean language composite scores (adjusted mean diﬀer-
ence, −1.42; 95% CI, −3.07 to 0.22; P = 0.09) of children
in the DHA group did not diﬀer from children in the control
group, although fewer children from the DHA group had cog-
nitive scores indicating delayed cognitive development com-
pared with controls (Makrides et al., 2010). At 4 years of age,
703 were eligible for follow-up and 646 (91.9%; n = 313 in
DHA group and n = 333 in control group) were included in
the analysis. Mean GCA scores of children born to women in
the DHA group did not diﬀer from children from women in the
control group (adjusted mean diﬀerence 0.29, 95% CI –1.35 to
1.93, P = 0.73) and there was no diﬀerence in the proportion
of children with impaired (GCA < 85) or advanced (GCA >
115) performance between the groups (Makrides et al., 2014).
These data support the most recent systematic review assess-
ing the eﬀect of DHA interventions during pregnancy on the
neurodevelopmental outcomes of children (Gould et al., 2013)
and indicates that in largely well-nourished populations DHA
supplementation has negligible benefit on longer term devel-
opmental outcomes. This is perhaps not surprising as the vast
majority of children would have experienced the full benefit of
in utero DHA transfer until term birth.
Allergy: our data showed that there was no significant dif-
ference in the overall percentage of children with IgE mediated
allergic disease in the first 3 years of life between the DHA
and control groups (64/368 (17.3%) vs. 76/338 (22.6%); ad-
justed relative risk 0.78; 95% CI 0.58–1.06; P = 0.11) (Palmer
et al., 2013). At 1 year of age, the percentage of infants diag-
nosed as having atopic eczema was lower in the DHA group
(26/368 (7%) vs. 39/338 (12%); unadjusted relative risk 0.61,
0.38 to 0.98, P = 0.04; adjusted relative risk 0.64, 0.40 to
1.02, P = 0.06) and fewer infants were sensitised to egg in the
DHA group (34/368 (9%) vs. 52/338 (15%); unadjusted rel-
ative risk 0.61, 0.40 to 0.91, P = 0.02; adjusted relative risk
0.62, 0.41 to 0.93, P = 0.02) (Palmer et al., 2012). However,
these findings did not persist at 3 years of age. It may be that
the eﬀects were diluted as the children grow by other environ-
mental factors or that any eﬀect of n-3 LCPUFA, like DHA,
in the prenatal period are smaller than originally anticipated.
The non-significant risk reductions of up to 22% may still be
of public health significance however, as the burden and cost
of allergic disease on aﬀected families are high, and fish oil
intervention is safe and relatively cheap.
In conclusion, our DOMInO study with a relatively typ-
ical and large sample of pregnant women has demonstrated
that DHA supplementation during the last half of pregnancy
significantly increases the duration of gestation and that this
results in a reduction in the number infants who are born very
preterm and low birth weight. The importance of this finding is
of potential global importance because of the high morbidity
associated with early preterm birth. It is interesting to note that
the direct longer term eﬀects of prenatal supplementation were
either not evident (such as the reduction in postpartum depres-
sion or enhanced neurodevelopment in the children) or rela-
tively short term (such as the reduction in atopic eczema at 1
but not 3 years of age). It may be that the eﬀect on these longer
term outcomes is small and therefore not easily detectable and
not clinically significant or that longer periods of supplemen-
tation may be needed.
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